Literature DB >> 31935523

Stability and bioactivity of pepCD47 attachment on stainless steel surfaces.

Vaishali V Inamdar1, Emmett Fitzpatrick1, Ivan Alferiev2, Chandrasekaran Nagaswami3, Lynn A Spruce4, Hossein Fazelinia4, George Bratinov5, Steven H Seeholzer4, Robert J Levy6, Ilia Fishbein7, Stanley J Stachelek8.   

Abstract

In-stent restenosis (ISR) and late stent thrombosis are the major complications associated with the use of metal stents and drug eluting stents respectively. Our lab previously investigated the use of peptide CD47 in improving biocompatibility of bare metal stents in a rat carotid stent model and our results demonstrated a significant reduction in platelet deposition and ISR. However, this study did not characterize the stability of the pepCD47 on metal surfaces post storage, sterilization and deployment. Thus, the objective of the present study was 1) to test the stability of the peptide post - storage, sterilization, exposure to shear and mechanical stress and 2) to begin to expand our current knowledge of pepCD47 coated metal surfaces into the preclinical large animal rabbit model. Our results show that the maximum immobilization density of pepCD47 on metal surfaces is approximately 350 ng/cm2. 100% of the pepCD47 was retained on the metal surface post 24 weeks of storage at 4 °C, exposure to physiological shear stress, and mechanical stress of stent expansion. The bioactivity of the pepCD47 was found to be intact post 24 weeks of storage and ethylene oxide sterilization. Finally our ex vivo studies demonstrated that compared to bare metal the rabbit pepCD47 coated surfaces showed - 45% reduced platelet adhesion, a 10-fold decrease in platelet activation, and 93% endothelial cell retention. Thus, our data suggests that pepCD47 coating on metal surfaces is stable and rabbit pepCD47 shows promising preliminary results in preventing thrombosis and not inhibiting the growth of endothelial cells. STATEMENT OF SIGNIFICANCE: Biocompatibility of bare metal stents is a major challenge owing to the significantly high rates of in-stent restenosis. Previously we demonstrated that peptide CD47 functionalization improves the biocompatibility of bare metal stents in rat model. A similar trend was observed in our ex vivo studies where rabbit blood was perfused over the rabbit pepCD47 functionalized surfaces. These results provide valuable proof of concept data for future in vivo rabbit model studies. In addition, we investigated stability of the pepCD47 on metal surface and observed that pepCD47 coating is stable over time and resistant to industrially relevant pragmatic challenges.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD47; Cell activation; Cell attachment; Peptide; Stability; Surface modification

Mesh:

Substances:

Year:  2020        PMID: 31935523      PMCID: PMC7295035          DOI: 10.1016/j.actbio.2019.12.039

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  31 in total

1.  Stent thrombosis: no longer an issue with newer-generation drug-eluting stents?

Authors:  Giulio G Stefanini; Stephan Windecker
Journal:  Circ Cardiovasc Interv       Date:  2012-06       Impact factor: 6.546

Review 2.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.

Authors:  Mark P Chao; Irving L Weissman; Ravindra Majeti
Journal:  Curr Opin Immunol       Date:  2012-02-04       Impact factor: 7.486

3.  Enhanced biocompatibility of CD47-functionalized vascular stents.

Authors:  Joshua B Slee; Ivan S Alferiev; Chandrasekaran Nagaswami; John W Weisel; Robert J Levy; Ilia Fishbein; Stanley J Stachelek
Journal:  Biomaterials       Date:  2016-02-08       Impact factor: 12.479

Review 4.  Inactivation of animal and human prions by hydrogen peroxide gas plasma sterilization.

Authors:  C Rogez-Kreuz; R Yousfi; C Soufflet; I Quadrio; Z-X Yan; V Huyot; C Aubenque; P Destrez; K Roth; C Roberts; M Favero; P Clayette
Journal:  Infect Control Hosp Epidemiol       Date:  2009-08       Impact factor: 3.254

5.  The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation.

Authors:  Stanley J Stachelek; Matthew J Finley; Ivan S Alferiev; Fengxiang Wang; Richard K Tsai; Edward C Eckells; Nancy Tomczyk; Jeanne M Connolly; Dennis E Discher; David M Eckmann; Robert J Levy
Journal:  Biomaterials       Date:  2011-03-22       Impact factor: 12.479

Review 6.  A new proposed simplified classification of coronary artery bifurcation lesions and bifurcation interventional techniques.

Authors:  Mohammad-Reza Movahed; Curtiss T Stinis
Journal:  J Invasive Cardiol       Date:  2006-05       Impact factor: 2.022

Review 7.  Coronary stents: historical development, current status and future directions.

Authors:  Javaid Iqbal; Julian Gunn; Patrick W Serruys
Journal:  Br Med Bull       Date:  2013-03-26       Impact factor: 4.291

8.  Ethylene Oxide and Hydrogen Peroxide Gas Plasma Sterilization: Precautionary Practices in U.S. Hospitals.

Authors:  James M Boiano; Andrea L Steege
Journal:  Zentralsterilisation (Wiesb)       Date:  2015

9.  Comparison of the endothelial coverage in everolimus and zotarolimus-eluting stents in normal, atherosclerotic, and bifurcation rabbit iliac arteries.

Authors:  Sho Torii; Gaku Nakazawa; Takeshi Ijichi; Ayako Yoshikawa; Yohei Ohno; Yuji Ikari
Journal:  Cardiovasc Interv Ther       Date:  2016-11-07

10.  Evidence that the red cell skeleton protein 4.2 interacts with the Rh membrane complex member CD47.

Authors:  Isabelle Mouro-Chanteloup; Jean Delaunay; Pierre Gane; Virginie Nicolas; Mette Johansen; Eric J Brown; Luanne L Peters; Caroline Le Van Kim; Jean Pierre Cartron; Yves Colin
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

View more
  1 in total

1.  Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization.

Authors:  Stanley J Stachelek; Ilia Fishbein; Vaishali V Inamdar; Emmett G Fitzpatrick; Ivan S Alferiev; Robert J Levy
Journal:  J Vis Exp       Date:  2020-12-03       Impact factor: 1.355

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.